University of Tennessee Health Science Center | Preventive Medicine

Research site

(Unclaimed)

Location

66 N. Pauline Street, Suite 647, Memphis, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Bevacizumab

Paclitaxel

Doxorubicin Hydrochloride

Ropeginterferon

Cyclophosphamide

Sorafenib Tosylate

Anastrozole

Bosentan

Tamoxifen Citrate

Lyrica

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 97 total trials

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Active, not recruiting

Essential Thrombocythemia

Drug: Ropeginterferon alfa-2b-njft (P1101)

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

Active, not recruiting

Polycythemia Vera

Drug: P1101 (Ropeginterferon alfa-2b-njft)

Drug: Ropeginterferon alfa-2b-njft (P1101)

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Active, not recruiting

Chronic Kidney Disease

Type 2 Diabetes Mellitus

Drug: Finerenone (BAY94-8862 ) 20 mg

Drug: Finerenone Placebo

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.This study will evaluate the safety and effects of...

Active, not recruiting

Metastatic Uveal Melanoma

Metastatic Ocular Melanoma

Combination Product: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patie...

Active, not recruiting

Hormone-resistant Prostate Cancer

Stage IV Prostate Cancer

Drug: prednisone

Drug: abiraterone

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profi...

Active, not recruiting

Hemophilia B

Biological: Factor IX (FIX)

Genetic: AAV5-hFIXco-Padua

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the preven...

Active, not recruiting

Necrotizing Enterocolitis

Drug: IBP-9414

Drug: Placebo

S0820, Adenoma and Second Primary Prevention Trial (PACES)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting

Colorectal Neoplasms

Drug: Eflornithine placebo & sulindac placebo

Drug: Eflornithine plus sulindac

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Daratumumab/rHuPH20

Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinom...

Enrolling

Endometrial Cancer

Drug: Matching Placebo for selinexor

Drug: Selinexor